Post-meal coagulation activation in diabetes mellitus: The effect of acarbose

Diabetologia

Volumn 39, Issue 4, 1996, Pages 469-473

  Ceriello, A ^a   Taboga, C ^b   Tonutti, L ^b   Giacomello, R ^a   Stel, L ^a   Motz, E ^a   Pirisi, M ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Acarbose; D dimer; Hyperglycaemia; Meal; Prothrombin fragments 1 + 2; Thrombophilia

Indexed keywords

ACARBOSE; GLUCOSE; INSULIN; PLACEBO; PROTHROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029863531     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00400679     Document Type: Article

References (38)

1. Ostermann H, van de Loo J (1986) Factors of the hemostatic system in diabetic patients. A survey of controlled studies. Haemostasis 16: 386-416
2. Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36: 1119-1125
3. Aronson DL, Stevan L, Ball AP, Franza BR Jr, Finlayson JS (1977) Generation of the combined prothrombin activation peptide (F1.2) during the clotting of blood and plasma. J Clin Invest 60: 1410-1418
4. Graeff H, Hafter R (1982) Detection and relevance of cross linked fibrin derivatives in blood. Semin Thromb Hemost 8: 57-68
5. Ceriello A, Giacomello R, Colalutto A, Taboga C, Gonano F (1992) Increased prothrombin fragment 1 + 2 in type I diabetic patients. Haemostasis 22: 50-51
6. Myrup B, Rossing P, Jensen T, Gram J, Kluft C, Jespersen J (1995) Procoagulant activity and intimal dysfunction in IDDM. Diabetologia 38: 73-78
7. Van Wersch JWJ, Westerhuis LWJJM, Venekamp WJRR (1990) Coagulation activation in diabetes mellitus. Haemostasis 20: 263-269
8. Ceriello A, Taboga C, Giacomello R et al. (1994) Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 43: 430-432
9. Ceriello A, Giacomello R, Stel G et al. (1995) Hyperglycemia-induced thrombin formation in diabetes: the possible role of oxidative stress. Diabetes 44: 924-928
10. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1037-1057
11. Pelzer H, Schwarz A, Stuber W (1991) Determination of human prothrombin activation fragment F1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 65: 153-159
12. Rylatt DB, Blake AS, Cottis LE et al. (1983) An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 31: 767-778
13. Mallia AK, Heremenson GT, Krohn RS, Fujimoto EK, Smith PK (1981) Preparation and use of a boronic acid affinity chromatography for separation and quantification of glycosylated hemoglobin. Analyt Lett 14: 649-661
14. Altman DG (1991) Clinical trials. In: Altman DG (ed) Practical statistics for medical research. Chapman & Hall, London pp 440-476
15. Boisclair MD, Ireland H, Lane DA (1990) Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 4: 25-40
16. Jones RL (1985) Fibrinopeptide A in diabetes mellitus: relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 34: 836-841
17. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R (1989) Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 38: 1162-1163
18. Jones RL, Peterson CM (1979) Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest 63: 485-493
19. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R (1988) Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 31: 889-891
20. Ceriello A, Quatraro A, Marchi E, Barbanti M, Giugliano D (1993) Impaired fibrinolytic response to increased thrombin activation in type I diabetes mellitus: the effect of the glycosaminoglycan sulodexide. Diabete Metab 19: 225-229
21. Hunt FA, Rylatt DB, Hart RA, Bendesen PG (1985) Serum cross-linked fibrin (SDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol 60: 715-722
22. Schneider DJ, Nordt TK, Sobel BE (1993) Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 42: 1-7
23. Vuorinen-Markkola H, Puhakainen I, Yki-Jävinen H (1992) No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost 7: 117-120
24. Garcia MJ, McNamara PM, Gordon T, Kannel WB (1974) Morbidity and mortality in diabetes in the Framingham population. Sixteen year follow-up study. Diabetes 23: 105-111
25. Ceriello A, Falleti E, Giacomello R et al. (1995) Evidence for a correlationship between coagulation activation and adhesion molecule ICAM-1 increase in diabetes. Diabetes 44: 636 (Abstract)
26. Colwell JA (1993) Vascular thrombosis in type II diabetes mellitus. Diabetes 42: 8-11
27. Theroux P, Latour JG, Leger-Gauthier C, De Lara J (1987) Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 75: 156-162
28. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE (1987) Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 317: 1361-1365
29. Wilson PWF, Cupples LA, Kannel WB (1990) Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 121: 586-590
30. Kuusisto J, Mykkänen L, Pyörälä K, Laasko M (1994) NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43: 960-967
31. Barret-Connor E, Wingard DL, Criqui MH, Suarez L (1984) Is borderline fasting hyperglyccmia a risk factor for cardiovascular death? J Chronic Dis 37: 773-779
32. Yarnell JWG, Pickering JE, Elwood PC et al. (1994) Does non-diabetic hyperglycemia predict future IHD - evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol 47: 383-388
33. Singer DE, Nathan DM, Anderson KM, Wilson PWF, Evans JC (1992) Association of Hb A1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41: 202-208
34. Swars H, Hafner G, Erbel R et al. (1991) Prothrombin fragments and thrombotic occlusion of coronary stents. Lancet 337: 59-60
35. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ (1994) Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90: 2236-2240
36. Giansante C, Fiotti N, Cattin L, Da Col PG, Calabrese S (1994) Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemost 71: 581-586
37. Ceriello A, Pirisi M, Giacomello R et al. (1994) Fibrinogen plasma levels as a marker of thrombin activation: new insights of the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 71: 593-595
38. Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118: 956-963